Alnylam Pharmaceuticals Inc.
Alnylam, a pipeline‑heavy RNAi biopharma, has FDA‑approved ONPATTRO, GIVLAARI, OXLUMO and Leqvio and a diverse portfolio of phase II/III candidates for rare & metabolic diseases, backed by strategic collaborations with Regeneron, Novartis, and Sanofi.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 2,230
- HQ: Cambridge
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.